Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
about
Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted ApproachesInfluence of APOE Genotype on Alzheimer's Disease CSF Biomarkers in a Spanish PopulationPlasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging.Plasma β-amyloid in Alzheimer's disease and vascular disease.Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease.Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.Relationship between APOE Genotype and Structural MRI Measures throughout Adulthood in the Study of Health in Pomerania Population-Based Cohort.PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid BiomarkersAlzheimer's disease CSF biomarkers: clinical indications and rational use.Comparing Plasma Phospho Tau, Total Tau, and Phospho Tau-Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load.Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly.Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects.Targeted metabolomics and medication classification data from participants in the ADNI1 cohort.Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease?Inhibiting the Ca2+ Influx Induced by Human CSF.Imaging and CSF analyses effectively distinguish CJD from its mimics.APOE genotype and early β-amyloid accumulation in older adults without dementia.Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer's disease.A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor.Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.Dysregulation of the epigenetic landscape of normal aging in Alzheimer's disease.Relationship between cytokine levels in the cerebrospinal fluid and 11C-Pittsburgh compound B retention in patients with mild cognitive impairment.Revolution of Alzheimer Precision Neurology Passageway of Systems Biology and Neurophysiology.Diagnostic Validity of an Automated Probabilistic Tractography in Amnestic Mild Cognitive Impairment.Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer's disease progression
P2860
Q26770708-E9D7EC4D-4BC3-4A5B-8D42-531FFB7F5A7DQ36764582-61E84D27-6383-4916-B3FE-78BE16E4D8FDQ36891744-00B9B721-571F-43D0-9D3C-E2BC433E63D5Q36949501-6AE158BD-BBBF-46B2-A027-7FD20B800579Q37204006-0B42956E-321D-478A-89DD-F59F8C137A82Q37410164-00299012-DFE9-457D-B49C-A7244A6BFA9DQ37500400-D05BA943-BB0F-4AEC-8BAE-CB44857A8264Q38628805-8C4D75B3-68C3-422A-81D8-6BA667FE1BD3Q38650548-7C7612CA-6C3F-4D92-8197-84123FA97D11Q38664719-BFA999E4-BF03-4552-9C08-36B221E0A303Q38979999-DB5074E6-EBF2-45EE-BCD2-75D50CCC4524Q39034863-470F4C73-2B8B-4A29-9649-7E219B4C630FQ39544835-B8890F9C-5855-43D6-9339-046E177D47ABQ40032161-7B012A59-58F7-498E-9715-05DA7428B7D7Q40285515-966A6A5E-DC2D-4371-8A68-A3C0CFF859B7Q42379364-D82328F6-FAC0-4AE9-AE21-886E6625C1C9Q47105654-5CC976A2-5B9A-4997-88CB-65F1A869126BQ47144784-D590F029-2BBE-4D3E-B3A8-0F1D6AA264C8Q47398462-05918483-8646-4825-8254-10AC30CAACD3Q47650724-FA7489F8-89E6-44C2-966D-C8BDDAB966B6Q47716188-A8B67F18-CBE3-401F-ABD1-26360CCDF55AQ47833026-9B7FBA6A-6E33-43E8-940D-18B7505D35DAQ48596415-8E68AD3C-4A54-4A21-88CF-FD0C8A4B2AA2Q50420748-98701C06-9D2C-442F-8168-7EFD3AC57582Q51110504-1E6151D9-A872-4ABF-9E4B-A421E324A0FEQ51760905-E8692189-DA1B-460A-ABFB-8ED41600AF97Q55436625-2C4164AD-CA30-48CF-9544-59EB6C41FAE4Q57940312-4487EDE2-804F-46C4-892F-9B397CC3CC82
P2860
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
@ast
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
@en
type
label
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
@ast
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
@en
prefLabel
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
@ast
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
@en
P2093
P2860
P50
P921
P356
P1433
P1476
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
@en
P2093
Abhay Moghekar
Ana Gorostidi
Argonde C van Harten
Gurutz Linazasoro
Hugo Vanderstichele
Jose A Monge Argilés
Jose L Molinuevo
Leslie M Shaw
Lorena Rami
Luisella Bocchio-Chiavetto
P2860
P304
P356
10.1093/BRAIN/AWV199
P407
P50
P577
2015-07-27T00:00:00Z